Aktis Oncology (NASDAQ:AKTS) Given Average Recommendation of “Buy” by Analysts

Aktis Oncology (NASDAQ:AKTS) has received an average recommendation of “Buy” from the five brokerages that are covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $32.00.

AKTS has been the topic of several recent research reports. Wall Street Zen upgraded Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. Leerink Partners initiated coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They issued an “outperform” rating and a $31.00 target price on the stock. TD Cowen started coverage on Aktis Oncology in a report on Tuesday, February 3rd. They set a “buy” rating on the stock. JPMorgan Chase & Co. started coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 target price for the company. Finally, Bank of America initiated coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 price target for the company.

Aktis Oncology Price Performance

AKTS opened at $17.37 on Friday. The stock’s fifty day simple moving average is $19.03. Aktis Oncology has a 52 week low of $14.72 and a 52 week high of $29.16.

More Aktis Oncology News

Here are the key news stories impacting Aktis Oncology this week:

• Positive Sentiment: HC Wainwright raised earnings estimates across 2026 and 2027 quarters and kept a “Buy” rating with a $33 price target — the analyst materially reduced expected losses for Q1–Q4 2026 (e.g., Q1: from ($0.64) to ($0.36); Q2: ($0.71) to ($0.38); Q3: ($0.77) to ($0.46); Q4: ($0.83) to ($0.51)) and lifted FY2026 and FY2027 loss estimates (FY2026: ($2.95) to ($1.72); FY2027: ($3.71) to ($2.35)). That optimism is likely driving buying interest. Aktis Oncology (NASDAQ:AKTS) Stock Price Expected to Rise, HC Wainwright Analyst Says
• Positive Sentiment: Aktis announced FDA clearance of investigational new drug (IND) applications for AKY-2519 and provided business updates and full‑year 2025 financial results — IND clearances are a clear clinical development catalyst that can increase the stock’s upside if trials progress on schedule. Aktis Oncology Announces FDA Clearance of INDs for AKY-2519
• Neutral Sentiment: Market data and coverage references (e.g., Barron’s stock page) provide third‑party visibility but add no immediate catalyst; useful for background research. Aktis Oncology Inc. — Barron’s
• Negative Sentiment: Despite upgrades and IND clearance, consensus fundamentals remain loss-making (current full‑year consensus ≈ ($0.43) EPS) and the stock trades below its 50‑day moving average—ongoing development risk, cash burn and execution risk could pressure the share price if clinical or financing developments disappoint.

Insider Transactions at Aktis Oncology

In other news, major shareholder Bioventures 2018 L.P. Mpm purchased 1,112,777 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was bought at an average price of $18.00 per share, with a total value of $20,029,986.00. Following the acquisition, the insider directly owned 10,260,064 shares of the company’s stock, valued at approximately $184,681,152. This represents a 12.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Ansbert Gadicke acquired 1,112,777 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was purchased at an average price of $18.00 per share, with a total value of $20,029,986.00. Following the transaction, the insider owned 10,260,064 shares in the company, valued at $184,681,152. This represents a 12.17% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have purchased 6,117,776 shares of company stock valued at $110,119,968. Corporate insiders own 3.30% of the company’s stock.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.